Ocrelizumab for multiple sclerosis New
There's more to see -- the rest of this topic is available only to subscribers.
"Ocrelizumab for Multiple Sclerosis New." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434549/all/Ocrelizumab_for_multiple_sclerosis_New. Accessed 02 June 2023.
Ocrelizumab for multiple sclerosis New. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434549/all/Ocrelizumab_for_multiple_sclerosis_New. Accessed June 2, 2023.
Ocrelizumab for multiple sclerosis New. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/434549/all/Ocrelizumab_for_multiple_sclerosis_New
Ocrelizumab for Multiple Sclerosis New [Internet]. In: Cochrane Abstracts. [cited 2023 June 02]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434549/all/Ocrelizumab_for_multiple_sclerosis_New.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Ocrelizumab for multiple sclerosis New ID - 434549 BT - Cochrane Abstracts UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434549/all/Ocrelizumab_for_multiple_sclerosis_New DB - Evidence Central DP - Unbound Medicine ER -